Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
BIOLASE, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
November 14, 2023, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the Company’s stockholders’ equity of $332,000 as of September 30, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BIOLASE, INC amended Eleventh Amendment to Credit Agreement with SWK Funding LLC valued at Amended principal amortization payments and minimum consolidated unencumbered liquid assets covenant (effective 2023-11-15).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- SWK Funding LLC
- Value
- Amended principal amortization payments and minimum consolidated unencumbered liquid assets covenant
- Effective
- 2023-11-15
Exact text from the filing
On November 15, 2023, BIOLASE, Inc., a Delaware corporation (the “Company”), entered into the Eleventh Amendment to Credit Agreement (the “Eleventh Amendment”) with SWK Funding LLC (“SWK”), in connection with that certain Credit Agreement (the “Credit Agreement”), by and among the Company, SWK, and the lender parties thereto.
View on SEC.gov